VolitionRx is a publicly traded life sciences company that develops innovative solutions for blood-based diagnostics of different types of cancers. The company is focusing particularly on the development of detection measures for early-stage cancers, of which it believes that current diagnostics measures are inadequate.
At the basis of VolitionRx's development efforts is Nucleosomics®, the company's proprietary, non-invasive technology that measures and determines nucleosome structures within human blood. When cancer cells die, they release nucleosomes into the blood, providing a medical opportunity for actual cancer detection. Dr. Jay Micallef, VolitionRx's Chief Scientific Officer, says that there are many cancer diagnostics tests available that only detect a patient's risk of cancer. By being able to detect and determine the number of nucleosomes present within a patient's blood, however, Nucleosomics builds on top of these current measures' capabilities: it detects whether cancer is actually present.
Currently, VolitionRx is focusing its primary development efforts on colorectal cancer, a deadly cancer that is one of the deadliest in the United States. According to the Center for Disease Control and Prevention, in 2010 over 130,000 people were diagnosed with colorectal cancer in the United States. The American Cancer Society reports that chances for incidence of colorectal cancer increase as a person ages: some 9 out of 10 patients who are diagnosed with colorectal cancer are over 50 years of age.
This age trend is medically relevant considering the longer lifecycles of today's aging populations. Historically unprecedented amounts of Americans are moving into the elderly stage of life and requiring greater amounts of medical attention. To illustrate: beginning in 2011, each day an additional 10,000 Americans have reached 65 years of age, a daily trend that will likely persist until around 2030. With these increased requirements for sophisticated and available medical care, the healthcare sector has become more needing of medical technologies that are inexpensive, accurate, and scalable-especially in regard to cancer diagnostics.
VolitionRx helps fill this medical gap by providing diagnosis methods that are more likely to detect cancer in its early stages, instead of the later stages of affliction when patient survival rates drop. In short, by making early-stage cancer detectable, VolitionRx's diagnostic tests will substantially increase a patient's chances for cancer survival.
Backed by the efforts of a business-savvy corporate and scientific management, VolitionRx may be on the cusp of changing mainstream methods for cancer diagnosis in the United States-and the world.
For more information, visit: volitionrx.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com